Tag Archive for: radiopharma

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

/in

NorthStar will supply non-carrier added Actinium-225, a radionuclide, for use with Ariceum’s first-in-class radiopharmaceutical drug, satoreotide Berlin, Germany, and Beloit, Wisconsin, 11 December 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization […]

Read more

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

/in

Berlin, Germany, December 5, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, today announced the signing of a global supply agreement for the medical radionuclides […]

Read more

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

/in

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical development Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used 100% survival with a single dose of 30 kBq 225Ac-satoreotide but […]

Read more

Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024

/in

SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple times more potent than SST2 agonist, 225Ac-DOTATATE Satoreotide demonstrated durable complete response in standard murine xenograft models of Small Cell Lung Cancer in animal models, versus tumor growth delay with 225Ac-DOTATATE Berlin, Germany, 10 June, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of […]

Read more

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

/in

Berlin, Germany, 5 March 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the opening of its new laboratory facilities on 7 March at its Berlin headquarters to house the research and development of its next generation radiopharmaceutical pipeline candidates […]

Read more